(COFB) Cofinimmo - Ratings and Ratios

Exchange: BR • Country: Belgium • Currency: EUR • Type: Common Stock • ISIN: BE0003593044

COFB: Rental Properties, Healthcare Facilities, Offices, Nursing Homes

Cofinimmo SA, a seasoned player in the European real estate sector, has been navigating the market for four decades, specializing in the acquisition, development, and management of rental properties. Their diverse portfolio, valued at approximately €6.2 billion, is strategically spread across nine European countries, including Belgium, France, and Germany, positioning them as a significant player in the region.

The companys mission revolves around providing high-quality spaces for care, living, and work, directly enhancing the well-being of their occupants. This focus is evident in their substantial healthcare real estate portfolio, worth about €4.6 billion, a sector that offers stability and growth due to consistent demand for healthcare services.

As an independent entity, Cofinimmo adheres to stringent corporate governance standards and sustainability practices, which are crucial for investor confidence. Their operational efficiency is supported by a team of around 155 professionals across key European cities, ensuring effective portfolio management and tenant services.

Cofinimmos listing on Euronext Brussels and its REIT status in Belgium, France, and the Netherlands underscore its commitment to attracting investors through favorable tax structures. The oversight by the Financial Services and Markets Authority (FSMA) adds a layer of regulatory compliance, further bolstering investor trust.

From a financial standpoint, Cofinimmo boasts a market capitalization of around €2.08 billion. The forward P/E ratio of 8.90 indicates expectations for future earnings growth, while the P/B ratio of 0.60 suggests undervaluation relative to book value. The P/S ratio of 5.29 highlights a premium pricing, reflecting the quality and stability of their portfolio.

In summary, Cofinimmo SA presents an attractive investment opportunity with a strong focus on healthcare real estate, robust governance, and a strategic European presence, supported by favorable financial metrics.

Additional Sources for COFB Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

COFB Stock Overview

Market Cap in USD 2,492m
Sector Real Estate
Industry REIT - Healthcare Facilities
GiC Sub-Industry Diversified REITs
IPO / Inception

COFB Stock Ratings

Growth 5y -45.7%
Fundamental -
Dividend 82.4%
Rel. Strength -5.23
Analysts -
Fair Price Momentum 67.13 EUR
Fair Price DCF -

COFB Dividends

Dividend Yield 12m 20.95%
Yield on Cost 5y 14.69%
Annual Growth 5y 2.06%
Payout Consistency 93.7%

COFB Growth Ratios

Growth Correlation 3m 87.6%
Growth Correlation 12m -26.4%
Growth Correlation 5y -81.7%
CAGR 5y -6.69%
CAGR/Max DD 5y -0.12
Sharpe Ratio 12m 0.25
Alpha -4.22
Beta 0.859
Volatility 19.81%
Current Volume 103.3k
Average Volume 20d 80.8k
What is the price of COFB stocks?
As of April 03, 2025, the stock is trading at EUR 59.30 with a total of 103,319 shares traded.
Over the past week, the price has changed by -2.95%, over one month by +1.54%, over three months by +5.14% and over the past year by +7.43%.
Is Cofinimmo a good stock to buy?
Probably not. Based on ValueRay Analyses, Cofinimmo (BR:COFB) is currently (April 2025) not a good stock to buy. It has a ValueRay Growth Rating of -45.74 and therefor a somwhat technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COFB as of April 2025 is 67.13. This means that COFB is currently undervalued and has a potential upside of +13.2% (Margin of Safety).
Is COFB a buy, sell or hold?
Cofinimmo has no consensus analysts rating.
What are the forecast for COFB stock price target?
According to ValueRays Forecast Model, COFB Cofinimmo will be worth about 72.5 in April 2026. The stock is currently trading at 59.30. This means that the stock has a potential upside of +22.26%.
Issuer Forecast Upside
Wallstreet Target Price 65.2 9.9%
Analysts Target Price - -
ValueRay Target Price 72.5 22.3%